PharmaPoint: Chronic Obstructive Pulmonary Disease – Global Drug Forecast and Market Analysis to 2025

2017-05-30
Price :
Published : May-2017
No. of Pages : 317

PharmaPoint: Chronic Obstructive Pulmonary Disease – Global Drug Forecast and Market Analysis to 2025

Summary

COPD is a progressive lung disease characterized by an abnormal inflammatory response and airflow obstruction that is not fully reversible. Chronic airflow limitation is caused by both small airway diseases, such as obstructive bronchiolitis, as well as parenchymal destruction, including emphysema. Research suggests that the pathogenesis of COPD involves both genetic and environmental factors. The fourth leading cause of death in the world, COPD progresses slowly and symptoms, including shortness of breath, wheezing, chest tightness, cough, and increased mucous production, worsen over time.

Chronic obstructive pulmonary disease (COPD) treatment originated from asthma treatment and exacerbating individuals benefited from the ICS/LABA drug class, leading to even higher sales for GSK’s Advair and AstraZeneca’s Symbicort. Boehringer Ingelheim’s Spiriva (tiotropium) was introduced in the COPD treatment management in 2002, and has since become a global blockbuster as a COPD-targeted therapy with a remarkable impact on patients’ quality of life.

It estimated that the 2015 COPD drug sales to be US$9.9 Billion across the eight major pharmaceutical markets 8MM covered in this report. By the end of the forecast period in 2025, sales will increase to US$14.1 Billion at a Compound Annual Growth Rate (CAGR) of 3.7%, which includes seven pipeline therapies.

COPD is a market with a substantial number of unattained unmet needs, including stakeholders’ recognition of symptoms, treatment that reverses the progression of COPD, and identification of biomarkers. This is not very common for a disease with such an established treatment management and numerous marketed drugs. This is because of the multifactorial causes of the disease combined with a low diagnosis rate across the 8MM. COPD is called the ‘smoker’s disease’ since many of the afflicted individuals are or have been smokers for an extended period of their lives.

Boehringer Ingelheim was the market leader in 2015 with sales of US$3.2 Billion between Striverdi Respimat, Spiriva HandiHaler and Respimat, and Spiolto Respimat across the 8MM. GSK lagged behind with sales of US$2.4 Billion across the LABA, LAMA, LABA/LAMA, and ICS/LABA drug classes, followed by AstraZeneca with sales of US$1.5 Billion between Tudorza Pressair, Duaklir Genuair, and Symbicort. Novartis fell behind with sales of US$443.3 million without a blockbuster therapy in the COPD market.

The report “PharmaPoint: Chronic Obstructive Pulmonary Disease – Global Drug Forecast and Market Analysis to 2025”, Overview of COPD, including epidemiology (mMRC and CAT patient population), etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

In depth, this report provides the following analysis –
– Topline COPD market revenue from 2015-2025. ACOT and major pipeline product sales in this forecast period are included.
– Presents the key metrics for chronic obstructive pulmonary disease (COPD) in the eight major pharmaceutical markets (8MM) – the US, 5EU (France, Germany, Italy, Spain, and the UK), Japan, and Australia-during the forecast period from 2015-2025.
– Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting COPD therapeutics sales in the 8MM.
– Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
– Analysis of the current and future market competition in the global COPD therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Novartis, Sunovion.

Scope

– Overview of COPD, including epidemiology (mMRC and CAT patient population), etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
– Topline COPD market revenue from 2015-2025. ACOT and major pipeline product sales in this forecast period are included.
– Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting COPD therapeutics sales in the 8MM.
– Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
– Analysis of the current and future market competition in the global COPD therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to –
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
– Develop business strategies by understanding the trends shaping and driving the global COPD therapeutics market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the COPD therapeutics market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : GlobalData
More Reports
Title Price Buy Now

Company Profile: 23andMe

Company Profile: 23andMe Summary 23andMe is a personal genomics and biotechnology company that leverages machine learning technology to provide DNA analysis services. It also offers web-based interactive tools to individuals, helping them understand their own genetics information. Scope The report provides information and insights into 23andMe, including - - Overview of the company and its product offering - Detailed insight into its business operation, technology, revenue model, geographical presence and business model - Information on partnerships, funding and awards it received - Biography of top management. Reasons to buy - Gain insights into 23andMe's business operations. - Gain insights into funding and partnerships. - Gain understanding about its technology focus and success ......
$350

Company Profile: Fitbit, Inc.

Company Profile: Fitbit, Inc. Summary Fitbit, Inc. (Fitbit) offers a range of connected health and fitness devices that monitors various health parameters like sleep duration, heart rate, BMI, calories burned, exercise routines, etc. Scope The report provides information and insights into Fitbit, Inc., including - - Overview of the company and its product offering - Detailed insight into its business operation, technology, revenue model, geographical presence and business model - Information on partnerships, funding and awards it received - Biography of top management. Reasons to buy - Gain insights into Fitbit business operations. - Gain insights into funding and partnerships. - Gain understanding about its technology focus and success factors.......
$350

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – India

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - India Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - India". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in India. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of India. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by ......
$1995

The State of the Microbiome

The State of the Microbiome Summary GlobalData's "The State of the Microbiome", report provides an assessment of how the pharmaceutical industry perceives the state of the microbiome, including the challenges associated with developing, launching, and manufacturing microbiome therapeutics as well as where opportunity remains to invest in the microbiome space. Scope - Microbiome investment - determine level of activity and investment in the development of microbiome therapeutics by therapy area - Identify the challenges associated with - Developing microbiome therapeutics - Launching microbiome therapeutics - Manufacturing microbiome therapeutics. Reasons to buy - Develop and design your corporate strategies in the microbiome space by understanding the challenges associated with devel......
$1495

Rheumatoid Arthritis: Epidemiology Forecast to 2027

Rheumatoid Arthritis: Epidemiology Forecast to 2027 Summary Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation of the joints, bone and cartilage erosion, and joint deformity. Additionally, the condition manifests itself in multiple joints in the body. In RA, the body's immune system attacks the lining of the joints, known as the synovial membrane, or synovium, causing an inflammatory response. The disease can lead to premature mortality, disability, and decreased quality of life. GlobalData epidemiologists used sources that provided the diagnosed incidence, diagnosed prevalence, and total prevalence of RA based on the 1987 American College of Rheumatology (ACR) criteria and International Classification of Diseases, Tenth Edition (ICD-10): M05 and M06. In 2......
$3995

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals – Q3 2018

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2018 Summary GlobalData's "Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2018", report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q3 2018. The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides informati......
$1500

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – China

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - China Summary GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - China". The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in China. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of China. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by ......
$1995

Bulimia Nervosa Global Clinical Trials Review, H2, 2018

Bulimia Nervosa Global Clinical Trials Review, H2, 2018 Summary GlobalData's clinical trial report, "Bulimia Nervosa Global Clinical Trials Review, H2, 2018" provides an overview of Bulimia Nervosa clinical trials scenario. This report provides top line data relating to the clinical trials on Bulimia Nervosa. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. ......
$2500

Chlamydia trachomatis Infections Global Clinical Trials Review, H2, 2018

Chlamydia trachomatis Infections Global Clinical Trials Review, H2, 2018 Summary GlobalData's clinical trial report, "Chlamydia trachomatis Infections Global Clinical Trials Review, H2, 2018" provides an overview of Chlamydia trachomatis Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Chlamydia trachomatis Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDa......
$2500

Cat Allergy Global Clinical Trials Review, H2, 2018

Cat Allergy Global Clinical Trials Review, H2, 2018 Summary GlobalData's clinical trial report, "Cat Allergy Global Clinical Trials Review, H2, 2018" provides an overview of Cat Allergy clinical trials scenario. This report provides top line data relating to the clinical trials on Cat Allergy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials ......
$2500
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy